Affimed Therapeutics
NASDAQ-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies.
Launch date
Employees
Market cap
€57.0m
Enterprise valuation
€36m (Public information from Sep 2024)
Share price
$3.96 AFMD
Company register number HRB 721206 (Mannheim)
Heidelberg Baden-Württemberg (HQ)
Financials
Estimates*
EUR | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Revenues | 21.4m | 28.4m | 40.4m | 41.4m | 8.3m | 5.0m | 6.8m |
% growth | (16 %) | 33 % | 42 % | 2 % | (80 %) | (40 %) | 36 % |
EBITDA | (31.0m) | (34.2m) | (64.0m) | (86.6m) | (104m) | - | - |
% EBITDA margin | (145 %) | (121 %) | (159 %) | (210 %) | (1255 %) | - | - |
Profit | (32.4m) | (41.4m) | (57.5m) | (86.0m) | (106m) | - | - |
% profit margin | (151 %) | (146 %) | (143 %) | (208 %) | (1280 %) | - | - |
R&D budget | 43.8m | 50.0m | 81.5m | 98.8m | 95.0m | - | - |
R&D % of revenue | 205 % | 176 % | 202 % | 239 % | 1148 % | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
$32.0m | Series B | ||
€20.0m | Series C | ||
€15.5m | Series D | ||
$14.0m | Debt | ||
$15.7m | Series E | ||
N/A | $56.0m | IPO | |
N/A | $37.1m | Post IPO Equity | |
€19.1m | Post IPO Equity | ||
N/A | $16.6m | Post IPO Equity | |
$96.0m | Post IPO Equity | ||
N/A | - | ||
N/A | $115m | Post IPO Equity | |
* | N/A | $90.0m | Post IPO Equity |
Total Funding | €78.9m |
Recent News about Affimed Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.